Results 71 to 80 of about 13,099 (221)
Adoptive Immunotherapy in Chimeras with Donor Lymphocytes [PDF]
, 2003 Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect of allogeneic marrow transplantation has long been known, but only recently have methods been developed to ...
Kolb, Hans-Jochem +8 more
core +1 more source
Chronic myeloid leukemia: past, present, future [PDF]
Einstein (São Paulo), 2011 The discovery of the Philadelphia chromosome in 1960, and of theBCR-ABL oncogene in 1984, enabled the development in subsequentyears of a targeted therapy that revolutionized the treatment of chronic myeloid leukemia, thus changing its natural history ...
Patricia Weinschenker Bollmann +1 more
doaj +4 more sources
Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells. [PDF]
PLoS ONE, 2012 BACKGROUND: The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia.
Ludovic Belle +6 more
doaj +1 more source
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT) [PDF]
Leukemia, 2002 We examined safety and efficacy of STI-571 in 24 bcr/abl-positive patients with CML post PBSCT. At start of STI-571 therapy, nine patients presented in blast crisis (BC) or in accelerated phase (AP), and 15 in chronic phase (CP). Patients were evaluated for hematologic, cytogenetic and molecular response, survival and toxicity.
Fischer, T. +13 more
openaire +3 more sources
Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia [PDF]
Farmacia Hospitalaria, 2015 Objectives: To describe the implementation of a new model face to face and remote pharmaceutical care with home delivery of tyronsine kinase inhibitors medicines for patients with chronic myeloid leukemia.
Begoña San José Ruiz +2 more
doaj +1 more source
JEADV Clinical Practice, Volume 5, Issue 1, Page 222-225, March 2026.ABSTRACT The term “atypical wounds” primarily refers to lesions with immunological or cancerous etiologies. However, these wounds can also be drug‐induced. We report about a 32‐year‐old man with a 6‐year history of chronic myelogenous leukemia (CML) and chronic graft‐versus‐host disease (cGvHD) following an HLA‐compatible allogeneic stem cell ...
E. K. Stuermer +3 more
wiley +1 more source
Biomolecular Concepts, 2021 The BCR-ABL oncogene is a tyrosine kinase gene that is over-expressed in CML. It inhibits the TGF-β1 signaling pathway. Due to resistance of cells to the tyrosine kinase inhibitor, STI-571, the combined effect of STI-571 and TGF-β1 on K562 cells was ...
Bakhshayesh Masoome +3 more
doaj +1 more source
Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions
MedComm, Volume 7, Issue 3, March 2026.Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu +9 more
wiley +1 more source
Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon? [PDF]
, 2011 No abstract ...
Gudmundur V Helgason +7 more
core +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2015 Objective: To evaluate trends in mortality among adults with myeloid leukemia in the Vale do Paraíba, State of São Paulo. Methods: Data from the Brazilian National Health Service database DATASUS provided the number of deaths caused by myeloid leukemia ...
Fernando Callera +2 more
doaj +1 more source